11 maggio 2021 14:35
Fonte: Adnkronos
#chimica-e-farmacia
- MONTREAL, May 11, 2021 /PRNewswire/ CellCarta, a global provider of precision medicine services, announced today the acquisition of Reveal Biosciences ( Reveal ), a San Diego California based computational pathology company offering cutting-edge artificial intelligence (AI)-based quantitative pathology and immunohistochemistry services to the biopharmaceutical industry. This acquisition further strengthens CellCarta s position as a leading provider of histopathology biomarker services and will enable the company to broaden its offering in AI-enabled multi-omic data analysis services and applications.
Reveal Biosciences has created a new generation of Pathology Intelligence™ to enhance research, clinical trials, and improve patient outcomes globally. Reveal s imageDx™ pathology platform combines cutting edge machine learning (ML)-AI with traditional histopathology to transform tissue biology into actionable data.
Precision Medicine Leader Caprion-HistoGeneX Rebrands as CellCarta
MONTREAL, Jan. 26, 2021 /PRNewswire/ –Â Caprion-HistoGeneX, a leading global provider of specialized precision medicine laboratory services to the biopharmaceutical industry, is pleased to announce its new corporate name, CellCarta, and brand identity.
The new name for the Montreal-headquartered company stems from the 2019 combination of contract research organization Caprion Biosciences, which specializes in immunology and proteomics services, and HistoGeneX, a provider of histopathology and genomics services based in Antwerp. Recently, CellCarta further expanded its scientific capabilities and geographic presence through the acquisitions of Nova Scotia-based Clinical Logistics Inc. and California-based Mosaic Laboratories LLC. As a result, CellCarta is well positioned to serve the global clinical trial requirements of its pharmaceutical and bio-tech clients with state-of-the-art facilities in the United States
26 gennaio 2021
MONTREAL, Jan. 26, 2021 /PRNewswire/ Caprion-HistoGeneX, a leading global provider of specialized precision medicine laboratory services to the biopharmaceutical industry, is pleased to announce its new corporate name, CellCarta, and brand identity.
The new name for the Montreal-headquartered company stems from the 2019 combination of contract research organization Caprion Biosciences, which specializes in immunology and proteomics services, and HistoGeneX, a provider of histopathology and genomics services based in Antwerp. Recently, CellCarta further expanded its scientific capabilities and geographic presence through the acquisitions of Nova Scotia-based Clinical Logistics Inc. and California-based Mosaic Laboratories LLC. As a result, CellCarta is well positioned to serve the global clinical trial requirements of its pharmaceutical and bio-tech clients with state-of-the-art facilities in the United States, Canada, Europe and China. CellCarta is backed by A